PART I Company Overview Spyre Therapeutics, Inc. (NASDAQ: SYRE) is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyres pipeline includes extended half-life antibodies targeting 47, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. Our Strategy Our goal is to develop next-generation therapeutics to redefine the standard of ca...
Q2 FY2026 — expected 2026-08-05
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-19 | 2025-12-31 | 0001636282-26-000020 | EDGAR | 108K words |
| 2025-02-27 | 2024-12-31 | 0001636282-25-000020 | EDGAR | — |
| 2024-02-29 | 2023-12-31 | 0001636282-24-000005 | EDGAR | — |
| 2023-03-02 | 2022-12-31 | 0000950170-23-005705 | EDGAR | — |
| 2022-03-08 | 2021-12-31 | 0001564590-22-008995 | EDGAR | — |
| 2021-03-18 | 2020-12-31 | 0001564590-21-014021 | EDGAR | — |
| 2020-02-24 | 2019-12-31 | 0001564590-20-005888 | EDGAR | — |
| 2019-03-07 | 2018-12-31 | 0001564590-19-006771 | EDGAR | — |
| 2018-03-13 | 2017-12-31 | 0001564590-18-005404 | EDGAR | — |
| 2017-03-23 | 2016-12-31 | 0001564590-17-005137 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-09-30 | 0001636282-25-000102 | EDGAR | 55K words |
| 2025-08-05 | 2025-06-30 | 0001636282-25-000089 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001636282-25-000049 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001636282-24-000083 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0001636282-24-000051 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001636282-24-000037 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001636282-23-000018 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0000950170-23-041590 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-020825 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0000950170-22-021529 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001564590-22-027895 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001564590-22-018006 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-19 | 0001636282-26-000022 | EDGAR | 4K words |
| 2026-01-12 | 0001193125-26-009894 | EDGAR | — |
| 2025-11-04 | 0001636282-25-000104 | EDGAR | — |
| 2025-10-15 | 0001193125-25-240237 | EDGAR | — |
| 2025-10-14 | 0001193125-25-237904 | EDGAR | — |
| 2025-08-05 | 0001636282-25-000091 | EDGAR | — |
| 2025-06-17 | 0001193125-25-141756 | EDGAR | — |
| 2025-06-02 | 0001636282-25-000063 | EDGAR | — |
| 2025-05-08 | 0001636282-25-000050 | EDGAR | — |
| 2025-03-06 | 0001193125-25-048423 | EDGAR | — |
261 total filings indexed. 229 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001636282 |
| Ticker | SYRE |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.spyre.com |
| Listed | 2016-04-07 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report